💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Remimazolam

CHEMBL4297526 Phase 4 Đã phê duyệt Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
439.3 g/mol
LogP
3.4
Phase
4

Remimazolam is an ultra-short-acting benzodiazepine sedative that enhances GABA-A receptor-mediated inhibitory neurotransmission to produce dose-dependent sedation and anxiolysis, and is rapidly hydrolyzed by tissue esterases to an inactive metabolite, providing predictable and titratable sedation with rapid recovery. It is approved for procedural sedation and induction and maintenance of general anesthesia.

Khối lượng phân tử

439,3000 g/mol

LogP

3,40

TPSA

69,40 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Bladder Cancer Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Parkinson's Disease Bipolar Disorder Generalized Anxiety Disorder Inflammatory Bowel Disease Chronic Kidney Disease Stroke Obesity Gastroenterology Type 2 Diabetes Chronic Pain Atrial Fibrillation Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)CC[C@@H]1N=C(c2ccccn2)c2cc(Br)ccc2-n2c(C)cnc21

                

                

                
                

                    
InChI

                    
InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H19BrN4O2

                    

                    
                    

                        
HBD / HBA

                        
- / 5

                    

                    
                    

                        
Liên kết có thể quay

                        
5

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
28

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
Remimazolam is an ultra-short-acting benzodiazepine sedative that enhances GABA-A receptor-mediated inhibitory neurotransmission to produce dose-dependent sedation and anxiolysis, and is rapidly hydrolyzed by tissue esterases to an inactive metabolite, providing predictable and titratable sedation with rapid recovery. It is approved for procedural sedation and induction and maintenance of general anesthesia.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Remimazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4297526.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9867812.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.